BREXIN 20 mg, effervescent tablet 14 tablets
Active ingredients: Piroxicam, Piroxicam-beta-cyclodextrin complex
Commercialized according to BDPMDispensing in France: Prescription only
Effervescent tablet14 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BREXIN 20 mg, comprimé effervescent
- Pharmaceutical form
- comprimé effervescent(e)
- Route of administration
- orale
- Presentation description
- plaquette(s) thermoformée(s) aluminium polyéthylène de 14 comprimé(s)
- Marketing authorisation holder
- PIERRE FABRE MEDICAMENT
- Reimbursement according to BDPM
- 30%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Jun 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67229344CIP73487770CIP133400934877704Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PIROXICAMcomprimé | 20 mg · un comprimé | FT |
| PIROXICAM-BÉTACYCLODEXTRINE (COMPLEXE)comprimé | 191,20 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.